title: Search for new purine- and ribose-modified adenosine analogues as selective agonists and antagonists at adenosine receptors.
abstract: The binding affinities at rat A1, A2a, and A3 adenosine receptors of a wide range of derivatives of adenosine have been determined. Sites of modification include the purine moiety (1-, 3-, and 7-deaza; halo, alkyne, and amino substitutions at the 2- and 8-positions; and N6-CH2-ring, -hydrazino, and -hydroxylamino) and the ribose moiety (2'-, 3'-, and 5'-deoxy; 2'- and 3'- O-methyl; 2'-deoxy 2'-fluoro; 6'-thio; 5'-uronamide; carbocyclic; 4'- or 3'-methyl; and inversion of configuration). (-)- and (+)-5'-Noraristeromycin were 48- and 21-fold selective, respectively, for A2a vs A1 receptors. 2-Chloro-6'-thioadenosine displayed a Ki value of 20 nM at A2a receptors (15-fold selective vs A1). 2-Chloroadenin-9-yl(beta-L-2'-deoxy-6'- thiolyxofuranoside) displayed a Ki value of 8 microM at A1 receptors and appeared to be an antagonist, on the basis of the absence of a GTP-induced shift in binding vs a radiolabeled antagonist (8-cyclopentyl-1,3-dipropyl-xanthine). 2-Chloro-2'-deoxyadenosine and 2-chloroadenin-9-yl(beta-D-6'-thioarabinoside) were putative partial agonists at A1 receptors, with Ki values of 7.4 and 5.4 microM, respectively. The A2a selective agonist 2-(1-hexynyl)-5'-(N-ethylcarbamoyl)adenosine displayed a Ki value of 26 nM at A3 receptors. The 4'-methyl substitution of adenosine was poorly tolerated, yet when combined with other favorable modifications, potency was restored. Thus, N6-benzyl-4'-methyladenosine-5'-(N-methyluronamide) displayed a Ki value of 604 nM at A3 receptors and was 103- and 88-fold selective vs A1 and A2a receptors, respectively. This compound was a full agonist in the A3-mediated inhibition of adenylate cyclase in transfected CHO cells. The carbocyclic analogue of N6-(3-iodobenzyl)adenosine-5'-(N-methyluronamide) was 2-fold selective for A3 vs A1 receptors and was nearly inactive at A2a receptors.
authors.affiliation: Molecular Recognition Section, National Institute of Diabetes, and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland 20892-0810, USA.
authors.forename: S M
authors.initials: SM
authors.lastname: Siddiqi
authors.forename: K A
authors.initials: KA
authors.lastname: Jacobson
authors.forename: J L
authors.initials: JL
authors.lastname: Esker
authors.forename: M E
authors.initials: ME
authors.lastname: Olah
authors.forename: X D
authors.initials: XD
authors.lastname: Ji
authors.forename: N
authors.initials: N
authors.lastname: Melman
authors.forename: K N
authors.initials: KN
authors.lastname: Tiwari
authors.forename: J A
authors.initials: JA
authors.lastname: Secrist
authors.forename: S W
authors.initials: SW
authors.lastname: Schneller
authors.forename: G
authors.initials: G
authors.lastname: Cristalli
mesh_terms: D000241:Adenosine / Q000031:analogs & derivatives*; D000818:Animals; D016466:CHO Cells; D002462:Cell Membrane / Q000378:metabolism; D003342:Corpus Striatum / Q000378:metabolism; D006224:Cricetinae; D066298:In Vitro Techniques; D009682:Magnetic Resonance Spectroscopy; D058906:Purinergic P1 Receptor Agonists; D058915:Purinergic P1 Receptor Antagonists; D011687:Purines / Q000737:chemistry; D011869:Radioligand Assay; D051381:Rats; D011994:Recombinant Proteins; D012266:Ribose / Q000737:chemistry; D013329:Structure-Activity Relationship
chemical_list: D058906:Purinergic P1 Receptor Agonists; D058915:Purinergic P1 Receptor Antagonists; D011687:Purines; D011994:Recombinant Proteins; D012266:Ribose; D000241:Adenosine